Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.
about
GPs' decisions on drug treatment for patients with high cholesterol values: a think-aloud studyDescription and validation of a Markov model of survival for individuals free of cardiovascular disease that uses Framingham risk factorsPrevalence, predisposition and prevention of type II diabetes.Clinical guidelines on the management of hepatitis CPrimary prevention of coronary heart disease? What is cost effective in the clinical practice?Primary prevention of cardiovascular disease: cost-effectiveness comparisonEconomic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.Electron beam computed tomography: screening for coronary artery disease.Barriers and bridges to evidence based clinical practice.Preventing ischaemic heart disease in one general practice: from one patient, through clinical audit, needs assessment, and commissioning into quality improvement.What is the optimal age for starting lipid lowering treatment? A mathematical model.Using cost effectiveness information.Handling uncertainty in cost-effectiveness models.Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trialsThe association of low serum cholesterol with depression and suicidal behaviours: new hypotheses for the missing link.A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care.Introduction to health economics for the medical practitioner.Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.Cost effectiveness of statins in coronary heart disease.Effectiveness calculation in economic analysis: the case of statins for cardiovascular disease prevention.Variation in local policies and guidelines for cholesterol management: national survey.Cost-effectiveness analyses alongside randomised clinical trials.The Long-Term Cost to the UK NHS and Social Services of Different Durations of IV Thiamine (Vitamin B1) for Chronic Alcohol Misusers with Symptoms of Wernicke's Encephalopathy Presenting at the Emergency DepartmentA review of health care models for coronary heart disease interventions.Economic evaluations of cholesterol-lowering drugs: a critical and systematic review.Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney diseaseQuality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemia.Incorporation of economic evidence in the Dutch guideline 'cardiovascular risk management'.A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.Costs for screening, intervention and hospital treatment generated by the Malmö Preventive Project: a large-scale community screening programme.Design of cost-effective packages of care for non-insulin-dependent diabetes mellitus. Defining the information needs.General practitioner perceptions of treatment benefits and costs in patients with hyperlipidaemia.Omega-3 fatty acids and cardiovascular disease: The epidemiological evidence.Cost effectiveness of lowering cholesterol. Statin treatment should be started early.Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate.Cost effectiveness of lowering cholesterol. Study greatly underestimates the cost effectiveness of statin treatment.Newly licensed drugs.Cost effectiveness of lowering cholesterol. Study did not take account of confounders.Cost effectiveness of lowering cholesterol. Cost consequence analysis may be more useful to decision makers.Cost effectiveness of lowering cholesterol. Costs in general practice.
P2860
Q24792131-7B148403-7C6B-4610-8047-B52902620893Q24796318-99FECC73-980E-4FB3-B329-47823D580B88Q24815863-87D784E9-B114-45E2-A816-0794BFB08591Q27477946-7BEF6E0E-2DB7-43B5-8F14-186ADF3791D2Q28192987-463048FA-05EA-4C0E-9395-98B716EC2A67Q28217877-C021565D-1814-4B9C-B1DE-FF6E0B2264D0Q33631450-D92C7AE4-3299-4164-A076-57853B361093Q33732642-A3B34DC2-6224-4AF9-920F-A339413E3EDFQ33791205-B1B5F605-ED98-4647-B96C-F568A51FC500Q33792333-02D41184-6FBC-4A8D-8C0A-B97691C1A4EFQ33816882-D128E55D-C3AB-485F-B210-3AD292F2F684Q33821503-1D63C1ED-5BCD-490A-8CAE-2FF46861C316Q34025543-3DEBA45D-2C35-4F6D-B169-8D3404C000D1Q34065021-3DACDBFE-375C-48BA-A48E-4DDB848C26C0Q34146972-FACF86BD-834B-49B0-835A-9C309DF11901Q34224196-B9F7D2AD-5648-4DDE-BAAC-C29205974C68Q35107990-9E6E16C3-1D9D-418A-87D5-4F18E115A3A0Q35373645-D35B66EC-71AD-4865-A6D9-8A28C0FADA82Q35417723-6F87BD68-8896-4BDA-B548-A22E011C82C7Q35681298-B02E9DDA-08AA-4435-86C5-5A5038B183FEQ36601490-4F94130A-2627-45AA-8AB5-CD28B1C94B5CQ36684582-1D7F7E20-DECF-4BE6-BE49-3D8194B822EEQ36686020-32D3982F-C6F8-4303-B0D8-CB5156936BC3Q36691416-21169B99-BC6A-4952-B66E-CC6B491FB368Q36750107-5264F982-0186-4414-8CB5-8F5B163A190CQ36943996-E1ABB609-3ED1-496A-9F07-2C7B8EACD616Q37609307-7FC76C0E-4424-4AF7-AB75-33457C73E7E0Q37805717-C93404DC-93C8-4354-B493-1D16278599ECQ38992196-5CFEF7B4-EAEA-4613-A0D5-8A07C70E3287Q40659283-1E8C6A5D-626D-4DBB-BE66-6A15643D0552Q41600402-42D5E79A-F40A-435B-B1F8-20262D3A751DQ41778469-B1E789EA-8D27-4E5B-962C-6CFB854905E2Q42043145-BCFEBAB3-60D0-4B0B-96EA-A79B7A4725C9Q42680429-292A79FF-BA47-47B0-8A6D-9761C8E4EFA5Q42756655-50C6B5AB-58E1-4F4B-BFA6-BD39FEE516D0Q42973963-302253FA-D31B-4020-990B-F971593D1197Q43112947-F3D15D45-41B0-416F-8074-34E419E694B7Q43156398-75F9D21B-D271-4BCA-81D4-27E24BB476D7Q43190277-7103F7CE-CA8F-4537-89AA-C973AB3AC31DQ43190330-B2BC34A1-94C0-4F09-8FCC-85AD1476C086
P2860
Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Cost effectiveness of lowering ...... o health authority population.
@ast
Cost effectiveness of lowering ...... o health authority population.
@en
type
label
Cost effectiveness of lowering ...... o health authority population.
@ast
Cost effectiveness of lowering ...... o health authority population.
@en
prefLabel
Cost effectiveness of lowering ...... o health authority population.
@ast
Cost effectiveness of lowering ...... o health authority population.
@en
P2860
P1433
P1476
Cost effectiveness of lowering ...... o health authority population.
@en
P2093
P D Pharoah
P2860
P304
P356
10.1136/BMJ.312.7044.1443
P407
P577
1996-06-01T00:00:00Z